1. Balme HW (1954) Metastatic carcinoma of the thyroid successfully treated with thyroxine. Lancet 1: 812–813
2. Bartalena L, Martino E, Pacciarotti A, Grasso L, Aghini-Lombardi F, Buratti L, Bambini G, Breccia M, Pinchera A (1987) Factors affecting suppression of endogenous thyrotropin secretion by thyroxine treatment: retrospective analysis in athyreotic and goitrous patients. J Clin Endocrinol Metab 64: 849–855
3. Baudin E, Schlumberger M (1994) Levothyroxine treatment in patients with differentiated thyroid carcinoma. In: Orgiazzi J, Ledere J (eds) The thyroid and tissues. Schattauer, Stuttgart, pp 213–215
4. Biondi B, Fazio S, Carella C, Amato G, Cittadini A, Lupoli G, Sacca L, Bessastella A, Lombardi G (1993) Cardiac effects of long-term thyrotropin-suppressive therapy with levothyroxine. J Clin Endocrinol Metab 77: 334–338
5. Biondi B, Fazio S, Carella C, Sabatini D, Amato G, Cittadini A, Bellastella A, Lombardi G, Sacca L (1994) Control of adrenergic overactivity by b-blockade improves the quality of life in patients receiving long-term suppressive therapy with levothyroxine. J Clin Endocrinol Metab 78:1028–1033